Loading company
Organogenesis Holdings Inc.
ORGO · Nasdaq · ·
Next earnings: November 5, 2026
$1.39+1.1%Sep 29 close
- 1M
- -20.4%
- 6M
- -39.5%
- 1Y
- -67.2%
- 5Y
- -91.0%
ORGO · Nasdaq · ·
Next earnings: November 5, 2026
$1.39+1.1%Sep 29 close
Organogenesis Holdings Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $43.8M | $101M | -56.68% |
| Profit | -$96.3M | -$9.4M | -924.99% |
| Profit per share | -$0.77 | -$0.10 | -670.00% |
| Free Cash Flow | -$32.8M | -$36.5M | +10.29% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We are encouraged by signs of measured improvement in business trends in the second quarter, though the pace of recovery from the significant market contraction is slower than we expected,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Organogenesis Holdings Inc. is a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Organogenesis Holdings Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Organogenesis Holdings Inc. has no earnings call transcript available.